key: cord-0798501-7e6z41ip
authors: Zeng, Furong; Chen, Xiang; Deng, Guangtong
title: Convalescent plasma for patients with COVID-19
date: 2020-06-09
journal: Proc Natl Acad Sci U S A
DOI: 10.1073/pnas.2006961117
sha: 0f390115838d22d66ec2942d3c715ce84d32dad4
doc_id: 798501
cord_uid: 7e6z41ip

nan

in Shen et al.'s study (6) , blood was collected 10 days after discharge, and the duration from the onset of illness to blood collection was unclarified. The optimal time to collect the convalescent plasma needs to be clarified. Third, the total antibody dose (the transfused volume of convalescent plasma multiplied by SARS-CoV-2 neutralizing antibody titer) for adults needs further investigation. Enzyme-linked immunosorbent assay was used to test the SARS-CoV-2 neutralizing antibody titer in both studies. In the study by Duan et al. (3), 200 mL convalescent plasma with a neutralization titer above 640 was transfused, while 400 mL convalescent plasma with a neutralization titer above 1,000 was transfused in Shen et al.'s study (6) . Patients in both studies had positive clinical improvements. The optimal dose still needs to be clarified to help reduce the dosage of convalescent plasma and treat more patients. Finally, neither study described the previous severity of the COVID-19 donors. Whether convalescent plasma of COVID-19 donors with different degrees of severity has different therapeutic effects remains to be further investigated.

In conclusion, answering the above questions will help in defining the standards required for using convalescent plasma in severe or critical COVID-19 patients.

WHO, WHO virtual press conference on COVID-19

Convalescent plasma as a potential therapy for COVID-19

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Management of critically ill adults with COVID-19

Plasma treated with methylene blue and light: Clinical efficacy and safety profile

Treatment of 5 critically ill patients with COVID-19 with convalescent plasma

Clinical treatment of convalescent plasma for COVID-19

China Author contributions: X.C. and G.D. designed research; and F.Z. and G.D. wrote the paper. The authors declare no competing interest

To whom correspondence may be addressed. Email: dengguangtong@outlook.com or chenxiangck@126

This work was supported by Grants 81620108024 and 62041208 from the National Natural Science Foundation of China.